The Daiichi Pharmaceutical Co., Ltd has transferred all commercial rights for Plavix (clopidogrel) in Japan to Sanofi-aventis.

The transfer will be implemented in conformity with local regulatory requirements. Given their long-standing partnership, both parties agreed to collaborate in the future in the areas of manufacturing and co-promotion to ensure the success of Plavix in Japan. Plavix was submitted for registration to the Japanese ministry of health, labour and welfare on February 24, 2004 and its review is pending.

Daiichi’s main therapeutic and diagnostic areas of research include infectious diseases, cancer, cardiovascular disorders, cerebral and central nervous system illnesses, gastrointestinal ailments and immunological disorders.